FRI0165 RISK OF CKD IN MEMBRANOUS AND PROLIFERATIVE LUPUS NEPHRITIS - ANALYSIS OF A NATIONWIDE MULTICENTRE COHORT
Filipa Farinha(Instituto Politécnico de Santarém), María José Santos(University of Lisbon), Rodolfo Torres(Hospital de Egas Moniz), Diogo Fonsêca(Centro Hospitalar de Vila Nova de Gaia), M. Couto(Centro Hospitalar Tondela-Viseu), Ayman Abd El Aziz Abd El Rahman(University College London), Ana Rita Prata(Hospitais da Universidade de Coimbra), Miguel F Cunha, José Ariévilo Gurgel Rodrigues, R. Freitas(Câmara Municipal de Almada), C. Macieira, Ruth J. Pepper(University College Hospital), M. Luis(Hospitais da Universidade de Coimbra), Luís Inês(University of Beira Interior), Beatriz de Castro Barbosa dos Santos(Centro Hospitalar do Baixo Vouga), Sofia Barreira(Centro Hospitalar Lisboa Norte)
Cited by 1
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156